Podcasts about Ras

Surah 26 The Poets v202-212 Session 23 The Messenger ﷺ grave concern for his Ummah. Abū Mūsa Ash'ari (ra) narrates that Rasūlullah ﷺ said, "None is more tolerant than Allah SWT at hearing abuse. People attribute children to him, yet he pardons them and continues to feed them" (Bukharee).

Allâhü Zü'l-Celâl Kur'ân-ı Kerîm'inde şöyle buyuruyor: “(O vakit) Sen Allâh'tan bir esirgeme sayesindedir ki onlara yumuşak davrandın. Eğer (bilfarz) kaba, katı yürekli olsaydın, onlar etrâfından herhâlde dağılıp gitmişlerdi bile. Artık onları bağışla, (Allâh'tan da) günâhlarının bağışlanmasını iste. İş hususunda onlarla müşâvere et. Bir kere de azmettin mi artık Allâh'a güvenip dayan. Çünkü Allâh kendine güvenip dayananları sever.” (Ali İmran s. 159) Allâh (c.c.) kendisine güvenip dayananları sevdiğini bildiriyor. Tevekkülü sebebiyle Allâh (c.c.)'un sevdiği kimselerde de O'na karşı sevgi ve muhabbet olursa saâdete ereceği ve kurtulmuşlardan olacağı muhakkaktır.Allâhü Teâlâ, Kitab-ı Mübîn'inde Rasûlü (s.a.v.)'e şöyle bildiriyor: “De ki: “Allâh'ın bizim için yazdığından başkası asla bize erişmez. O, bizim Mevlâmızdır. Onun için mü'minler yalnız Allâh'a güvenip dayanmalıdır.” (Tevbe s. 51) Müslüman, herhangi bir üzüntü ve sıkıntı ile karşılaşınca Allâhü Teâlâ'ya olan güven ve tevekkülü sayesinde üzülüp tedirgin olmaz ve O'nun takdiri ile başına geldiğini bilir. Buradaki musibet ve sıkıntılar, bizim için ancak hayırdır. Zira bizim dâimi evimiz bu dünyada değil, âhirettedir. Asıl iyiliklerin buradan ziyâde âhirette elde edilmesi önemli ve gereklidir.Resûlullâh (s.a.v.) şöyle buyurmuşlardır: “Allâh (c.c.)'dan kendisine takdir olunana razı olması, kişinin saadetine vesiledir. Allâh (c.c.)'dan hayır dilemeyi bırakması da bedbahtlığındandır. Allâh (c.c.)'un takdir ettiklerine kızgın olması da aynı şekilde kişinin bedbahtlığındandır.”(Misvâk Neşriyat, Eşref Ali Et-Tehânevî, Hayâtü'l Müslimîn, s.122)

Feeling stuck in the manifestation gap — that frustrating space where your desires haven't arrived yet? In this episode, we're diving into why the delay doesn't mean it's not working, how to shift your mindset when you start to doubt, and what your brain is doing behind the scenes to filter your reality.You'll learn:Why the absence of evidence isn't evidence of absence (thank you, Price Pritchett).The iceberg model of manifestation (Freud meets manifestation).How your Reticular Activating System can either help or sabotage your manifestation.Why surrender is the secret to speeding things up.How to keep your signal clean, stay in alignment, and hold the vibe — even when nothing is showing up… yet.

V najnovšej epizóde podcastu suSPEAK na ŠPORT.sk privítali moderátori Marek Marušiak a Rasťo Konečný jednu z najväčších streleckých osobností slovenskej extraligy Romana Tománka. Takmer 40-ročný rodák z malebného Milochova v Považskej Bystrici sa otvorene rozhovoril o svojej bohatej kariére aj prešľapoch, ktoré ju ovplyvnili.Charizmatický útočník, ktorý bol v roku 2004 draftovaný Phoenixom Coyotes v rovnakom ročníku ako Alexander Ovečkin či Jevgenij Malkin, sa v rozhovore vrátil k hokejovým začiatkom. Ako chlapec, ktorého hokej bavil nielen na štadióne, ale aj mimo neho - či už pri vytváraní hokejok z čísel autobusov, alebo zo zemiakových vriec.Roman Tománek bol najlepším strelcom majstrovstiev sveta do 18 rokov, o prvenstvo sa delil s Philom Kesselom. Napriek talentu však v rozhovore priznáva, že vtedy ani nevedel, čo draft znamená.V najnovšej epizóde podcastu suSPEAK na ŠPORT.sk sa dozviete detaily aj o premiére Romana Tománka v kempe Phoenixu, kde neveril vlastným očiam, keď ho trénoval Wayne Gretzky. Rovnako úprimne porozprával aj o svojom pôsobení v zahraničí - od divokých zážitkov v Kazachstane, kde zažil cestu po púšti a aj ulomené koleso, až po nemeckú precíznosť v Rostocku.Fanúšikovia slovenského hokeja si určite vychutnajú spomienky na pôsobenie v Nitre, kde vytvoril obávané ofenzívne duo s Jozefom Stümpelom. Hovoril aj o tom, že v jednej sezóne mal po desiatom zápase 0+0, no nakoniec skončili s vyše 70 bodmi. Roman Tománek má na konte viac ako 40-gólovú sezónu v extralige a patrí k hokejistom, ktorým chýba vo vitríne len slovenský titul. Dvakrát sa dostal do finále - najprv s Nitrou, potom s Banskou Bystricou, vždy však ťahal za kratší koniec.V rozhovore si zaspomína na „staré časy” aj Rasťo Konečný, ktorý s Romanom Tománkom zdieľal spoločný ľad, a prezradil, ako vyzerali ich spoločné rozcvičky: „‚Gejzo' si zobral puk, ‚prešmotlal' a vystrelil. A my dvaja mu hovoríme, že by sme si mohli ten puk ešte vymeniť. A Gejzo: ‚Sorry, chalani. Ja si skúšam'.”Skúsený útočník, ktorý síce dnes stále hrá, ale zároveň už aj trénuje mládež v Považskej Bystrici, sa zamyslel aj nad pokračovaním svojej aktívnej kariéry: „V mojom veku je to v tomto smere už také, že ak to nebude mať význam, ani hlavu, ani pätu, tak to jednoducho ukončím.”Rozhovor uzatvoril úprimným odkazom mladým hokejistom, v ktorom upozornil, že jeho príbeh je príkladom toho, ako môžu byť blízko k rozprávkovej kariére, ale zároveň od nej aj ďaleko. Zdôraznil, že talent nestačí, dôležitá je drina a schopnosť požiadať v ťažkých chvíľach o pomoc.

V najnovšej epizóde podcastu suSPEAK na ŠPORT.sk privítali moderátori Marek Marušiak a Rasťo Konečný jednu z najväčších streleckých osobností slovenskej extraligy Romana Tománka. Takmer 40-ročný rodák z malebného Milochova v Považskej Bystrici sa otvorene rozhovoril o svojej bohatej kariére aj prešľapoch, ktoré ju ovplyvnili.Charizmatický útočník, ktorý bol v roku 2004 draftovaný Phoenixom Coyotes v rovnakom ročníku ako Alexander Ovečkin či Jevgenij Malkin, sa v rozhovore vrátil k hokejovým začiatkom. Ako chlapec, ktorého hokej bavil nielen na štadióne, ale aj mimo neho - či už pri vytváraní hokejok z čísel autobusov, alebo zo zemiakových vriec.Roman Tománek bol najlepším strelcom majstrovstiev sveta do 18 rokov, o prvenstvo sa delil s Philom Kesselom. Napriek talentu však v rozhovore priznáva, že vtedy ani nevedel, čo draft znamená.V najnovšej epizóde podcastu suSPEAK na ŠPORT.sk sa dozviete detaily aj o premiére Romana Tománka v kempe Phoenixu, kde neveril vlastným očiam, keď ho trénoval Wayne Gretzky. Rovnako úprimne porozprával aj o svojom pôsobení v zahraničí - od divokých zážitkov v Kazachstane, kde zažil cestu po púšti a aj ulomené koleso, až po nemeckú precíznosť v Rostocku.Fanúšikovia slovenského hokeja si určite vychutnajú spomienky na pôsobenie v Nitre, kde vytvoril obávané ofenzívne duo s Jozefom Stümpelom. Hovoril aj o tom, že v jednej sezóne mal po desiatom zápase 0+0, no nakoniec skončili s vyše 70 bodmi. Roman Tománek má na konte viac ako 40-gólovú sezónu v extralige a patrí k hokejistom, ktorým chýba vo vitríne len slovenský titul. Dvakrát sa dostal do finále - najprv s Nitrou, potom s Banskou Bystricou, vždy však ťahal za kratší koniec.V rozhovore si zaspomína na „staré časy” aj Rasťo Konečný, ktorý s Romanom Tománkom zdieľal spoločný ľad, a prezradil, ako vyzerali ich spoločné rozcvičky: „‚Gejzo' si zobral puk, ‚prešmotlal' a vystrelil. A my dvaja mu hovoríme, že by sme si mohli ten puk ešte vymeniť. A Gejzo: ‚Sorry, chalani. Ja si skúšam'.”Skúsený útočník, ktorý síce dnes stále hrá, ale zároveň už aj trénuje mládež v Považskej Bystrici, sa zamyslel aj nad pokračovaním svojej aktívnej kariéry: „V mojom veku je to v tomto smere už také, že ak to nebude mať význam, ani hlavu, ani pätu, tak to jednoducho ukončím.”Rozhovor uzatvoril úprimným odkazom mladým hokejistom, v ktorom upozornil, že jeho príbeh je príkladom toho, ako môžu byť blízko k rozprávkovej kariére, ale zároveň od nej aj ďaleko. Zdôraznil, že talent nestačí, dôležitá je drina a schopnosť požiadať v ťažkých chvíľach o pomoc.

Hoje recebemos o Dr Marcos Ávila especialista em retina pela Harvard Medical School, professor Titular de Oftalmologia da FM/UFG 1997, Ex presidente da SBRV, Ex presidente do CBO. E também recebemos o Dr Lucas Zago que é especialista em retina pela EPM e Coordenador Médico do Programa Olhar para Todos.No Episódio de hoje conhecemos os bastidores do Programa Olhar Para Todos: Um programa do Governo de Goiás que oferece atendimento oftalmológico gratuito a estudantes da rede pública estadual, incluindo exames, diagnóstico, entrega de óculos e encaminhamento para tratamentos, quando necessário. Já beneficiou mais de 20 mil alunos, visando melhorar o desempenho escolar e reduzir a evasão. A iniciativa, realizada em parceria com a UFG, SEDUC e OVG, pretende atender todos os mais de 495 mil estudantes até 2026. Material Suplementar:Livro: Saúde Ocular no SUS Vídeo sobre o projetoSite do Projeto Olhar Para TodosDetalhes sobre o Projeto:O Projeto tem objetivo de promover saúde ocular gratuita aos estudantes, por meio de avaliação, diagnóstico, acompanhamento especializado e entrega gratuita de óculos.O Governo de Goiás, por meio da Secretaria de Estado da Saúde (SES), em parceria com o Centro de Referência em Oftalmologia da Universidade Federal de Goiás (Cerof/UFG), Secretaria de Estado da Educação (SEDUC) e Organização das Voluntárias de Goiás (OVG), já atendeu 20.062 estudantes da rede pública estadual nos últimos 7 meses. O número corresponde a 64,1% dos alunos das escolas visitadas e que tiveram autorização dos pais/responsáveis.O Olhar Para Todos, lançado em novembro de 2024, é considerado o maior programa público de saúde oftalmológica do Centro-Oeste. Por meio de um consultório móvel, a ação disponibiliza oftalmopediatras e equipamentos de ponta nas escolas para realização de exames e, se necessário, oferta de óculos e/ou encaminhamento, via regulação estadual, para acompanhamento ambulatorial ou cirúrgico pelo Sistema Único de Saúde (SUS).O programa já esteve em 59 escolas da rede estadual de educação e encaminhou 1.201 estudantes para acompanhamento no Cerof/GO que oferece atendimento especializado em problemas oculares, como glaucoma, estrabismo, córnea, retina e outros. Dentre os estudantes atendidos 6.428 precisavam da prescrição de óculos, os quais foram ofertados pela OVG.O objetivo é estender a ação aos mais de 495 mil estudantes até 2026. A presidente de honra da OVG, primeira-dama Gracinha Caiado, destacou o alcance do programa Olhar Para Todos. “Não fazemos apenas o exame. Quem precisa de cirurgia também é atendido. “Fazemos isso para mostrar que não existe governo se não for para cuidar das pessoas”, afirmou.Segundo dados do Governo de Goiás, programas de exames e doação de óculos podem reduzir em 12% a repetência e a evasão escolar. O Secretário de Estado da Saúde, Rasível Santos, enfatizou a importância do projeto. “O Olhar para Todos assegura que os estudantes tenham acesso a consultas oftalmológicas e tratamentos necessários, garantindo melhores condições para alcançar bons resultados acadêmicos”, acrescentou.De acordo com o presidente do conselho administrativo do Cerof/UFG, Marcos Ávila, a iniciativa leva até a comunidade escolar consultórios modernos e completos, dispostos em ônibus, para oferecer atendimento de qualidade aos jovens pacientes. “Esse projeto é inovador em termos de diminuir a repetência, a evasão e tantos problemas que quem não enxerga enfrenta em uma sala de aula”, destacou. 

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Welcome back to Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives! In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, recapped highlights from the 2025 Endocrine Society annual meeting. They spotlighted advances, controversies, and ongoing unmet needs in type 1 diabetes care. 00:00:00 Intro 00:00:40 GLP-1 RAs in type 1 diabetes 00:05:50 Tirzepatide in type 1 diabetes 00:08:32 Cardioprotective therapies in type 1 diabetes 00:12:17 Type 1 diabetes Barbie and public education

In this bonus we run through the latest trending topics in popculture, starting with my review of Justin Bieber's new album SWAG and why it was NOT what I expected. We then discuss the execs caught cheating at a Coldplay concert and finish with the legal battle between toy company Epoch and the tiktok account SylvanianDrama! Kiss your sidepiece on the Jumbotron and most importantly - let me know what you think!Instagram - ⁠⁠⁠@moodforfeud⁠⁠⁠ TikTok - ⁠⁠⁠@moodforfeud ⁠⁠⁠⁠Support the show on ⁠⁠Ko-fi⁠⁠ all funds go towards upgrading my podcast gear!⁠⁠Timestamps00:54 SWAG album review13:55 Cheating scandal at the Coldplay concert24:57 Sylvanian Drama legal issuesIntro/Outro MusicYarWritten by Ryan SkeltonProduced by Ras & Sakunera#coldplaycheatingscandal #astronomer #swagalbum #justinbieber #sylvanianfamilies #sylvaniandrama #popculturenews #trendingtopics #legalissues

SummaryIn this episode of A Cup of Joe podcast, Joe Morton explores the interconnectedness of the reticular activating system (RAS) and the law of attraction, emphasizing the power of thoughts, emotions, and intentions in shaping our reality. He discusses how our beliefs and dominant thoughts filter our experiences and attract corresponding outcomes. The conversation delves into practical applications such as prayer, visualization, and mindfulness, highlighting the importance of setting intentions and nurturing a positive mindset to achieve personal goals and well-being. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit joemorton88.substack.com

MUSICDeftones will release their first album in five years, Private Music, on August 22nd. The first single is called "My Mind Is a Mountain," which you can check out on YouTube now. The album was produced by Nick Raskulinecz [pr: RAS-kell-in-ich], who sat in the producer's chair on 2010's Diamond Eyes and 2012's Koi No Yokan. https://www.youtube.com/watch?v=cgh_jEm5twE An old clip is resurfacing again from the Joe Rogan podcast where Jelly Roll sets some things straight. A bunch of people on the internet were calling his wife, Bunnie XO, a gold digger for being with him . . . but Jelly had the perfect answer. https://www.tiktok.com/@xomgitsbunnie/video/7234363257467817259 Jojo Siwa has teased a cover of Kim Carnes' classic '80s hit "Bette Davis Eyes", and Kim dissed it on an Instagram post that has since been deleted. Kim said "There's a difference between singing a song . . . And embodying it." Here's the clip Jojo posted. https://pagesix.com/2025/07/10/entertainment/kim-carnes-seemingly-shades-jojo-siwas-viral-betty-davis-eyes-cover/? The Yungblud documentary Are You Ready Boy? will be shown in theaters on August 20th and 24th. https://yungblud.film/ Ozzy Osbourne teamed up with some chimpanzees to create five paintings to sell at an auction to raise money for Save the Chimps. He says, quote, "I paint because it gives me peace of mind, but I don't sell my paintings. I've made an exception with these collaborations as it raises money for Save the Chimps . . . NEW ALBUM RELEASES:311 - 311 30th Anniversary Edition (two-LP set)Wet Leg - Moisturizer TVRick Springfield was disrespected not once, but TWICE on the "Today" show yesterday. The first diss happened before he even came out on the set. Al Roker was hyping Rick's appearance, and fellow hosts Savannah Guthrie, Jenna Bush Hager, and Kaylee Hartung started singing "867-5309 / Jenny". As EVERYONE should know, that's NOT a Rick Springfield song. It's by the FAR INFERIOR Tommy Tutone. https://www.dailymail.co.uk/media/article-14893911/today-rick-springfield-hosts-yawned-craig-melvin.html Check out a new trailer for the "King of the Hill" revival. https://www.hollywoodreporter.com/tv/tv-news/king-of-the-hill-revival-trailer-hulu-1236311177/ Larry David is returning to HBO one more time for a limited sketch comedy series about American history. David will star in six episodes. https://variety.com/2025/tv/news/larry-david-american-history-sketch-comedy-series-hbo-1236451946/ Tom Brady's representative has firmly denied claims that he ever said Sofía Vergara is “too old” to date him, calling such reports “pure fiction” and saying he “would never” make such a remark, according to People magazine. https://people.com/tom-brady-would-never-say-sofia-vergara-too-old-date-says-rep-exclusive-11770067?utm_source=chatgpt.com MOVING ON INTO MOVIE NEWS: IN THEATERS:Superman (Nicholas Hoult, Rachel Brosnahan, David Corenswet) The third installment of the 'Dune' franchise has an official title, 'Dune: Part Three.' Rumors spread that the movie would be called 'Dune Messiah', based off of the 1969 novel. https://variety.com/2025/film/news/dune-3-title-imax-cameras-1236448953/ AND FINALLYBefore some celebrities made it BIG, they did background work for movies, TV, and even music videos. BuzzFeed put together a list of some of these familiar faces. https://www.buzzfeed.com/trendyghost618/celebrities-who-started-as-extras AND THAT IS YOUR CRAP ON CELEBRITIES!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197SummaryEmerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Discuss emerging data on GLP-1 RA therapy for CKD progression in T2DImplement guideline-based care to minimize CV risk and CKD progressionThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

5 Quantum manifestation stages :1. Desire to evolve and do/be better. 2. RAS in your brain activated : lack, absence, comparison, triggers. 3. Frustration of dancing between two timelines : old & new. 4. Overcoming and overpowering resistance. 5. Imagination > illusions Private mentorship details : https://msha.ke/themetaphysicsmagic#private-mentorshipFor custom affirmation package or quantum communication course details , check my Instagram story highlights : https://www.instagram.com/themetaphysicsmagic/?hl=Message me to join now, talk to you soon

This week we deep dive into a feud between two of the most controversial and polarising internet personalities - Trisha Paytas and Ethan Klein and uncover the breakup of the Frenemies podcast. We cover how Trisha and Ethan became famous, discuss why they are so controversial, and explain the origin story for the Frenemies podcast. Although this episode is fairly lighthearted I do want to acknowledge that Trisha and Ethan are both problematic creators who have said incredibly harmful things that I completely disagree with. Do the honky tonky and most importantly - let me know what you think! Instagram - @moodforfeud TikTok - @moodforfeud ⁠Support the show on Ko-fi all funds go towards upgrading my podcast gear!Timestamps04:00 Trisha's notable popculture moments06:50 Trisha Paytas background16:20 The Trisha baby curse17:48 Ethan Klein background23:44 The feudIntro/Outro MusicYar Written by Ryan Skelton Produced by Ras & Sakunera#frenemies #frenemiesscandal #ethanklein #trishapaytas #ethankleincontroversy #trishapaytascontroversy #ethantrishafeud #h3h3productions #h3

Azra Sokira je mladá slovenská influencerka s výrazným balkánskym temperamentom. Ten ju zviditeľnil nielen na Farme, ale aj v tretej sérii reality šou Ruža pre nevestu. Vyspovedali sme ju v StarTalks s Ninou. V podcaste sa dozviete: Ako Azru vnímajú ľudia po skončení Ruže pre nevestu? Išla do šou hľadať lásku, alebo sa iba zviditeľniť? Ktorá séria mala podľa nej najlepšieho ženícha a vydržalo by to Azre s Rasťom aj v reálnom živote? S ktorými ružičkami si najviac a naopak najmenej rozumela a ktorú si na sociálnych sieťach zablokovala? Ako vzala fakt, že Miška na ňu pred Rasťom vytiahla, že mala na Farme sex na kamerách? Je nejaká situácia z Ruže, ktorú spätne ľutuje? Prečo drží svojho priateľa mimo záujmu médií a čo on hovorí na jej účinkovanie v Ruži? Taktiež budete počuť: Tolerovala by Azra u muža, keby sledoval na instagrame svoje ex? Akceptovala by, ak by bol muž nižší než ona? Ako by vnímala, ak by muž stále býval u matky a nevedel variť?

Reakciu na príchod Martiny Šimkovičovej na folklórny festival Východná môžu niektorí považovať za neslušnú, ale treba brať do úvahy aj aroganciu, s ktorou ministerka kultúry vystupuje, myslia si šéf reportérov Denníka N Juraj Koník a editor Rasťo Kačmár. V debate s reportérom Dušanom Mikušovičom hodnotia hlavné udalosti týždňa, vrátane obvinenia policajta Mateja Vargu, návrhu volebného zákona či problémov festivalu Rubicon. Lovte slová v novej hre Denníka N. Zahrajte si Slovosleď: www.dennikn.sk/slovosled

To celebrate the end of the RASTECH 2025 Conference and Trade Fair, Jean Ko Din sits down with her co-host, Justin Henry, and Howard Tang, CEO of Peritus Capital to talk about takeaways from the show in San Diego, Calif. Justin was session chair of a New Projects session that showcased new innovators in recirculating aquaculture, while Howard hosted the Investors' Forum to talk about the investment activity in RAS for the past year.

This is a rerelease of one of our popular episodes from our series on ballet summer intensives. Wondering how much the RAs see of student antics? More than you think! We're talking with Robert Fulton and Camille Kellems, both professional dancers and also RAs at ballet summer intensives. Get ready for a mix of insider info that's helpful for parents as well as hilarious anecdotes as Robert and Camille let us in on what really goes on behind the scenes. From dorm shenanigans to studio mishaps, they've seen it all and they're here to spill the tea.  Robert and Camille are also the founders of Ballet Scout. You can learn more about what they do on their website. Links: Support Ballet Help Desk Summer Intensive Essentials Guide Buy Summer Corrections Journals Instagram: @BalletHelpDesk Facebook: BalletHelpDesk Ballet Help Desk Music from #Uppbeat: https://uppbeat.io/t/ian-aisling/new-future License code: MGAW5PAHYEYDQZCI

Ras de tierra con Ana Laura Magaloni

30 Jun 2025. Air Asia aims to open a Gulf hub this year with four airports on the shortlist, including Ras al Khaimah. CEO Tony Fernandes shares the details. Plus, we get the inside story on G42’s rise to the global Top 100 - the company’s chief marketing officer joins us live. And with the UAE corporate tax deadline fast approaching, tax expert Vishal Sharma joins us to explain what businesses need to know and what exemptions may still apply.See omnystudio.com/listener for privacy information.

Success in RAS can come in all shapes and sizes. At RASTECH 2025 (June 9-10 in San Diego, Calif., USA), our keynote panel explores how their farms forged their own path of profitability, and on their own terms.Our panelists:Thorsten Vammen is the general manager of FREA Solutions, based in Denmark. FREA AS is fully recirculated facility raising rainbow trout in Felding, Denmark. Located just a few metres from FREA Solutions' headquarters, the facility has been operating since 2014, producing over 2,800 tonnes of fish annually across two 4,000 m² buildings.Sara Rademaker is the founder and CEO of American Unagi, a glass eel recirculating hashtag#aquaculture farm in Waldoboro, Maine. American Unagi is the first and only producer and processor in the U.S. of locally sourced and harvested American glass eel. The large-scale farm was built in 2023 to produce 240 tonnes annually and plans to double its capacity within the year.Yosuke Kurihara is the co-founder and CEO of ARK Inc. based in London, U.K. and Tokyo, Japan. Established in 2020, the company developed a small-scale, 10-square-metre Closed Recirculating Aquaculture System (CRAS) known as "ARK" that supports off-the-grid aquaculture with solar power generation and a solar hot water supply. There are currently six units installed and in operation in cities across Japan.

What if your brain has a built-in filtration system that's keeping you stuck in worry instead of manifesting your dreams? In this special bonus episode of Why Isn't Everyone Doing This?, I'm taking you deep into the science behind embodied manifesting and revealing why traditional manifestation techniques often fall short. Most people spend minutes every day "worshiping their worries"—obsessing over what could go wrong instead of focusing on what they'd love to create. But there's actual neuroscience behind why this happens, and more importantly, how to rewire it. I break down the reticular activating system (RAS), your brain's filter that determines what you notice in reality. When you're in chronic stress, this filter prioritizes threats over opportunities. But when you learn to regulate your nervous system first, then manifest from that grounded state, everything changes.

Joninių laužų poveikis oro kokybei. Rasų naktį Šiauliuose nušvis skulptūros. Kokias klaidas darome vasarą gamindami maistą? Kaip šienaujama žolė miestuose? Panevėžyje galima aplankyti buvusio Cukraus fabriko administracijos pastatą.Ved. Rūta Kupetytė

Send us a textEver feel like you're juggling flaming swords on a tightrope over a pit of to-do lists?Whether it's surprise invoices, deadline-pinging texts, or a mind that spirals straight to worst-case scenario mode… this episode is for the high-achiever who's ever found herself red-faced and frozen mid-Zoom call, wondering, “How am I going to pull all this off?”Join Alex and Carol for a raw, practical, and encouraging conversation about what really happens in our minds and bodies when overwhelm hits—and what to do about it.

What if the reason you're not seeing results in your business isn't your strategy, but your brain's filter system?  In this episode, we dive into the Reticular Activating System (RAS), the part of your brain that decides what you notice (and what you miss). You'll learn how subconscious beliefs shape what opportunities you see, what you believe is possible, and why your next level of success might be hiding in plain sight.   Tune in to explore how shifting your RAS can change your marketing, your mindset, and your momentum. And, how to start using this part of your brain to align more with opportunities and results that you want to create.    More resources: Book a free consultation: https://martinethomassen.com/free-marketing-audit Instagram: @martinethomassencoaching Show Notes: https://martinethomassen.com/post/ras  Website: https://martinethomassen.com Sign up to my newsletter and become a Holistic Marketing Insider   Certified with The Life Coach School (LCS), WellCoaches, The Neuroscience Academy and Simone Seol's BFCC.

Sometimes we meet people and we tell them something about Kṛṣṇa, give them a book, and it's not immediately evident, but later, we'll meet them. Or maybe we won't meet them, we'll meet somebody else who had an incidental contact with the devotee, and then they'll tell how everything started from that one statement. “I heard that thing. He said this, I read this one thing, and then it started.” And we're in a liminal state. Any minute we can cross back over into the spiritual environment by a little encouragement from the sound vibration, or by the same principle, we can always slip into nescience. But once the devotees have been awakened and have experienced the taste of Kṛṣṇa consciousness, even if they temporarily slip into darkness, it's not the same, Nārada Muni says, “as it is for somebody who's never experienced it, they always remember it.” Even though they become captured by Māyā, they still remember. As Viśvanātha Cakravartī Ṭhākura said, they're haunted by the ghost of rasa. Rasāgraha, he said, “they're grabbed by it.” They keep thinking, “Oh, yeah, but I remember that time.” So it's very poignant, what you said about the power of the sound. And the saṅkīrtana movement is based on that; it's spreading that same sound vibration, Bhagavad-gītā, and the holy names to other living entities. ------------------------------------------------------------ To connect with His Grace Vaiśeṣika Dāsa, please visit https://www.fanthespark.com/next-steps/ask-vaisesika-dasa/ ------------------------------------------------------------ Add to your wisdom literature collection: https://iskconsv.com/book-store/ https://www.bbtacademic.com/books/ https://thefourquestionsbook.com/ ------------------------------------------------------------ Join us live on Facebook: https://www.facebook.com/FanTheSpark/ Podcasts: https://podcasts.apple.com/us/podcast/sound-bhakti/id1132423868 For the latest videos, subscribe https://www.youtube.com/@FanTheSpark For the latest in SoundCloud: https://soundcloud.com/fan-the-spark ------------------------------------------------------------ #spiritualawakening #soul #spiritualexperience #spiritualpurposeoflife #spiritualgrowthlessons #secretsofspirituality #vaisesikaprabhu #vaisesikadasa #vaisesikaprabhulectures #spirituality #bhaktiyoga #krishna #spiritualpurposeoflife #krishnaspirituality #spiritualusachannel #whybhaktiisimportant #whyspiritualityisimportant #vaisesika #spiritualconnection #thepowerofspiritualstudy #selfrealization #spirituallectures #spiritualstudy #spiritualquestions #spiritualquestionsanswered #trendingspiritualtopics #fanthespark #spiritualpowerofmeditation #spiritualteachersonyoutube #spiritualhabits #spiritualclarity #bhagavadgita #srimadbhagavatam #spiritualbeings #kttvg #keepthetranscendentalvibrationgoing #spiritualpurpose

GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery. But what happens after the weight is lost? And can we really talk about success without talking about maintenance? While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next. Can lifestyle interventions alone sustain weight loss after GLP-1 cessation? How do metabolic adaptations and behavioral relapse factor in? And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications? In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management. Tara Schmidt is a registered dietitian and an instructor of nutrition at Mayo Clinic. As the lead dietitian for the Mayo Clinic Diet, she provides guidance rooted in evidence-based principles. She hosts the Mayo Clinic On Nutrition podcast and co-authored The Mayo Clinic Diet: Weight Loss Medications Edition. Timestamps [05:17] Understanding weight loss maintenance [08:44] Defining success in weight loss maintenance [11:54] Predictors of maintenance: self-monitoring and behavioral strategies [23:37] Pharmacological interventions: GLP-1 receptor agonists [31:06] Dietary considerations for those taking GLP-1 RAs [37:07] Addressing misconceptions about weight loss drugs [42:48] Final thoughts and takeaways [48:49] Key ideas (Premium-only) Links/Resources Subscribe to Sigma Nutrition Premium Go to episode page Join the Sigma email newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course Visit sigmanutrition.com

Dans ce nouvel épisode, on reçoit Esther Reporter qui vient nous parler de sa super BD. Camille nous révèle de lourds secrets, Kalindi fait peur à tout une salle de cinéma et Louise arrive ENFIN à se concentrer pour travailler.Esther Reporter sur InstagramLéa Castor sur InstagramLe crowdfunding de la BD « Ras Le Viol »Pour écouter le 5ème Quarts d'Heure, abonnez-vous à Supercast : https://4quartsdheure.supercast.com/Abonnez-vous à 4 Quarts d'Heure sur votre plateforme de podcast préférée : https://tr.ee/MEaR8W9S9GLes ups & downs :Le down de Camille : elle a failli être dans une secteLe rollercoaster d'Esther : sa BD « Ras le Viol »Le rollercoaster de Kalindi : elle n'allait plus assez au cinéma jusqu'à voir SinnersLe up de Louise : elle est de retour sur TwitchCe dont on parle : Le documentaire « Orgasmique le business de One Taste » (dispo sur Netflix)La BD « Ras le Viol » d'Esther Meunier et Léa CastorLe livre « Pas prêtes à se taire » d'Esther Meunier et Léa CastorLe collectif @NotreOhrageLe compte Instagram @Surviv_HanteLe film « Sinners » de Ryan CooglerUn article (en anglais) sur le hoodooLa chaîne Twitch de LouiseLes jeux Wordle, Spotle, Heardle, BandleNTS RadioLa chaîne Twitch de MymyLe café Off Campus à ParisSuivez-nous sur Instagram :4 Quarts d'Heure : @4quartsdheureLouise : @petrouchka_Alix : @alixmrtnKalindi : @kalramphulCamille : @camille.lorente Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Motoristický publicista a recenzent Rasťo Chvála v novej epizóde podcastu Autobazar.EU hovorí o svojich začiatkoch, o príjmoch z produkcie videí o autách a tiež o budúcnosti mediálneho trhu s auto-moto tematikou. Nielen spravodajské médiá prechádzajú významným vývojom, ale aj tie zamerané na automobily, motocykle a vôbec dopravu. Slovensko je v porovnaní s českým trhom oveľa menej konkurenčný, novinári sú skôr komunitou, hovorí Rasťo Chvála v rozhovore s Erikom Strížom z Autobazar.EU, a uvádza konkrétne príklady.V rozhovore sa Stríž pýta aj na to, či môžu diváci veriť motoristickým novinárom, keď sú ich videá platené automobilkami, ako vyzerá zákulisie produkcie a spoločne hľadajú odpovede na otázky spojené s polarizáciou verejnosti kvôli elektromobilom. Odkazy zmienené v rozhovore:Web Garáž.TV: https://garaz.tv/ YouTube Rasťa Chválu: https://www.youtube.com/@RastoChvalaofficial Prehodnotenie plánov EÚ k roku 2035: https://magazin.autobazar.eu/necakany-zvrat-europska-unia-ustupuje-klasicke-auta-dostavaju-druhu-sancu-clanok8987.html

Wondering how to turn your high-performing content into a compelling lead magnet? Join us in this episode of Launch Your Private Podcast as we coach Joyce Layman, a seasoned visibility strategist and author, on how to transform her mindset-based content into a private podcast lead magnet that deeply resonates with her audience.Joyce came into the conversation with content that outperforms everything else, but it's centered around mindset, not marketing tactics. Together, we unpack how to align what's working with what she's selling and how to use private podcasting to bridge the gap between curiosity and conversion.Timestamps:[0:00] Intro to Joyce Layman and why her audience is tired of social media[5:56] Joyce walks through her membership, group program, and micro offers[7:41] Her audience struggles with tech and low-performing lead magnets[9:18] Repurposing a PDF into a private podcast that leads to her offers[13:02] Joyce plans to enhance and restructure her lead magnet content[16:19] Her top-performing episodes are about mindset and the RAS[18:33] Using mindset as the “holy sh*t” moment to build belief early[22:12] Messaging ideas like “Train your brain to be seen” take shape[28:06] How a private podcast can bridge mindset and visibility strategy[32:14] Final recommendation: test both the PDF and RAS audio lead magnets[35:19] Joyce previews her upcoming Micro Audio SummitLinks mentioned:http://www.joycelayman.comIf you enjoyed today's episode, please:Post a screenshot & key takeaway on your IG story and tag us at @helloaudiofm so we can repost you.Leave a positive review or rating at https://ratethispodcast.com/lyppGrab a free trial of Hello Audio: helloaudio.fm/pricing

Trevor Gent, director of Engineered Solutions at Alumichem, delves into the critical role of wastewater treatment in recirculating aquaculture systems (RAS). As a "fish poop expert," he emphasizes the importance of early planning and integration of waste management systems. He discusses various treatment options, highlighting the need for regulatory compliance and market development.

Episode 284: Summer has officially begun, and we're diving into everything from backyard baseball memories to how summer traffic and summer hours impact our daily lives. But beyond the nostalgia, we're focusing on what's truly important for your flower shop: summer goals, mindset, and staying ahead!Join Lori and Vonda as they explore how the Reticular Activating System (RAS) in our brains shapes what we see, what we notice, and how it impacts our daily interactions... yes, even in the flower shop! From positivity and team culture to customer service and product inspiration, we'll talk about how to harness RAS to bring your summer goals to life.We also bring on our special guest, Marissa Guerrero, to talk about the Texas State Floral Expo coming up at the end of June. She shares all the “secrets” and nuggets of knowledge you'll gain by attending this in-person event, and why showing up in real life matters more than ever in our AI-driven world!Texas State Floral Expo Information and Registration LinkSponsored by: Flower CliqueFlower Clique Prep SchoolReal Life Retail Florist

Act Two of Five: In the deepest darkest basement, the former Mayor has a lead that could go all the way to the top.Coming next on 17 June – Vigil: Shadowfall, Act 3Programme notesThis production contains fantasy violence, gunfire, and references to child abduction.In chapter 3 of Camera Obscura, Matt's actual play of Outliers by Samantha Leigh, the RAs do battle with a dæmon-haunted server.Dramatis personae and other definitionsMelody Bantham: The owner of Melodies, the cosy cafe and vinyl shop on Market Street. Melody is an ageless patchwork person animated by music, who fled her creator ages ago and has owned a music shop on this spot ever since.Harper: A US exchange student trying to sever her ties to the Shadow realm she sometimes enters through revolving doors.Gwynned, the Shieldmaiden: A former shieldmaiden of the triple goddess Morrigan, exiled to live as a duck for the crime of saving a mortal man from her mistress' cruel whim, now freed from her curse and elevated to a third of the godhead herself.Brier: A mischievous shapeshifting púca, the fae guardian of Sherrydown's Rosebrier Forest.Department of Omissions (DO, DoOm): The UK government department tasked with preventing harm to citizens from supernatural phenomena. Severely defunded under Tory austerity policies and currently prioritising major urban population centres.Sherrydown, Brackshire: A historic English market town. One of the first towns to lose its DoOm office.Omission effect: The rejection of certain beings and phenomena by long-term memory. Recently lifted.CreditsCOMPERE: Matt BoothmanSTARRING:Helen Stratton as Melody Bantham, the ConstructedMarta Da Silva as Harper, the SearcherNatalie Winter as Gwynned, the DivineStrat as Brier, the MonstrousROLEPLAYING GAME SYSTEM: Monster of the Week, designed by Michael SandsMUSIC BY: Alexander PankhurstSOUND DESIGN BY: Matt BoothmanSFX AND INCIDENTAL MUSIC INCLUDES: Pigeons taking off by Glaneur de sons on freesound.org (CC BY 4.0); and may include others made available to use without attribution.EDITED AND PRODUCED BY: Matt BoothmanFind usOn Instagram @MerelyRoleplayersOn Tumblr @merelyroleplayerswww.MerelyRoleplayers.com

In this episode, host Ken Vinacco interviews Franchino Porciuncula, the winner of the DDSIG platform award at CSM 2025 in Houston, TX. They discuss his research related to utilizing closed-loop, music-based rhythmic auditory stimulation (RAS) with people with Parkinson's Disease (PD). They review the impact on real-world walking and gait quality, as well as participant feedback. He discusses ways to integrate use of RAS in clinic, highlighting both the complex nature of PD and challenges and limitations observed in this randomized clinical trial.   The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuroPT.org Show notes: https://app.box.com/s/yqos32rt9wf5ofdshnsiwedxh8ftny7i

Israel has authorised 22 new Jewish settlements in the occupied West Bank, including legalising unauthorised outposts.Such settlements are considered illegal under international law - a designation Israel disputes.There's nothing new about settlements, they've been popping up in the area since 1967. But since the Hamas attack on 7 October, tensions have intensified.On the Sky News Daily, Niall Paterson is joined by our international correspondent Alex Rossi and producer Orly Halpern, who have visited the Palestinian village of Ras al-Ayn, where activists on the ground have reported a surge in violence and intimidation by Israeli settlers aimed at driving Palestinian families from their homes.Editor: Philly BeaumontProducer: Jada Kai Meosa John

On this episode of The Wholesome Fertility Podcast, I am joined by Dr. Nirali Jain (eggspert_md), a board-certified OB/GYN and reproductive endocrinologist at Reproductive Medical Associates (RMA). Dr. Jain shares her expert insights on fertility preservation for individuals undergoing cancer treatment, a crucial yet often overlooked aspect of reproductive care. We explore what options are available for fertility preservation, including egg and sperm freezing, and why it's so important to initiate these discussions before starting chemotherapy or radiation. Dr. Jain also explains the difference between Letrozole and Clomid, the impact of estrogen-sensitive cancers on IVF treatments, and innovative approaches like random-start cycles and DuoStim protocols. Whether you're facing a cancer diagnosis or simply thinking proactively about your reproductive future, this conversation is filled with knowledge and reassurance. Key Takeaways: Why it's essential to discuss fertility before starting cancer treatment. The role of Letrozole in estrogen-sensitive cancers and fertility preservation. Differences between Letrozole and Clomid, and why Letrozole is often preferred. How new protocols like DuoStim and random-start cycles are improving outcomes. Why fertility preservation is important even for those without a cancer diagnosis. Guest Bio: Dr. Nirali Jain (@eggspert_md) is a board-certified OB/GYN and fertility specialist at Reproductive Medicine Associates (RMA) in Basking Ridge, New Jersey. She earned both her undergraduate degree in neurobiology (with a minor in dance!) and her medical degree from Northwestern University, before completing her residency at Weill Cornell/NYP, where she served as co-Chief Resident, and her fellowship in reproductive endocrinology and infertility at NYU Langone. Deeply passionate about women's health and fertility preservation, Dr. Jain blends the latest research and cutting-edge treatments with compassionate, patient-centered care. Her interests include third-party reproduction and oncofertility, and she is especially passionate about supporting patients navigating fertility preservation through a cancer diagnosis. Outside of the clinic, Dr. Jain is a trained dancer, a dedicated global traveler, and an adventurer working toward hiking all seven continents with her husband. Her diverse experiences, from international medical rotations to personal connections with friends and family navigating infertility, have shaped her into a warm, resourceful, and determined advocate for her patients. Links and Resources: Visit RMA websiteFollow Dr. Nirali Jain on Instagram For more information about Michelle, visit www.michelleoravitz.com To learn more about ancient wisdom and fertility, you can get Michelle's book at: https://www.michelleoravitz.com/thewayoffertility The Wholesome Fertility facebook group is where you can find free resources and support: https://www.facebook.com/groups/2149554308396504/ Instagram: @thewholesomelotusfertility Facebook: https://www.facebook.com/thewholesomelotus/ Disclaimer: The information shared on this podcast is for educational and informational purposes only and is not intended as medical advice. Please consult with your healthcare provider before making any changes to your health or fertility care. --  Transcript:   # TWF-Jain-Nirali (Video) ​[00:00:00]  **Michelle Oravitz:** Welcome to the podcast Jain.  **Dr. Nirali Jain:** Thanks so much for having me **Michelle Oravitz:** Yeah, so. **Michelle Oravitz:** I'm very excited to talk about this topic, which, um, actually you don't really hear a lot of people talking about, which is how to preserve your fertility if you're going through a cancer diagnosis and if you have to go through treatments. 'cause obviously that can impact a lot on fertility. **Michelle Oravitz:** I have, um, seen actually like a colleague of mine go through. And she also preserved her fertility and, and now she has a baby boy. so it's really nice. **Michelle Oravitz:** to **riverside_nirali_jain_raw-video-cfr_michelle_oravitz's _0181:** so nice. **Michelle Oravitz:** So I'd love for you first to introduce yourself and kind Of give us a background on how you got into this work. **Dr. Nirali Jain:** Of course. Um, so I am Dr. Narly Jane. I am, um, an OB GYN by training, and then I did an additional, after completing four years of residency in OB GYN and getting board certified in that, I did an additional training in reproductive endocrinology and [00:01:00] infertility or otherwise known as REI. So now I'm a fertility specialist. **Dr. Nirali Jain:** Um, I trained at Northwestern in Chicago, so I went to undergrad and medical school there. And then, um, home has always been New Jersey for me, so I moved back out east to New Jersey. Um, I did all my training actually in New York City at Cornell for residency and NYU for fellowship. Um, and then moved to the suburbs. **Dr. Nirali Jain:** Um, and now I'm a fertility specialist in, in Basking Ridge at Reproductive Medical Associates.  **Michelle Oravitz:** Very impressive background. That's awesome.  **Dr. Nirali Jain:** Yeah. **Michelle Oravitz:** I'd love to hear just really. About what your process is. If a person has been diagnosed with cancer, like what is the process? What are some of the things that you address if they are trying to preserve fertility, and what are some of the concerns going  **Dr. Nirali Jain:** yeah, yeah. All great questions. So, you know, there's a lot of us, uh, the Reis. Are a very small, [00:02:00] there's a very small number of us. So in terms of specializing in fertility preservation, technically we all are certified to treat patients with cancer and kind of move them through fertility preservation before starting chemotherapy. **Michelle Oravitz:** Mm-hmm.  **Dr. Nirali Jain:** Um, luckily we've been working closely with oncologists in the past several years just to establish some type of streamlined system because having a diagnosis of cancer and hearing all that information. Especially when you're young is so hard. So I think that's, that's where my interest started in terms of being able to speak to and counsel cancer patients. **Dr. Nirali Jain:** I think it is a very specific niche that you really have to be comfortable with in our field. Um, I. So I'll kind of walk you through, you know, what it, what does it look like, right? Um, you go into your oncologist's office suspecting that you have this, this lump. I'll take breast cancer, for example. It could really be any kind of cancer. **Dr. Nirali Jain:** Um, but breast cancer in a reproductive age patient or someone that's in those years where you're starting [00:03:00] to think about building a family, planning a family, um, or if you have kids at home, that's usually the type of patient that we see come in with a breast cancer diagnosis. So. Kinda just taking that, for example, um, the minute that you're diagnosed, it's really your oncologist's responsibility to counsel you on what treatment options are going to be offered to you. **Dr. Nirali Jain:** And then based off of the treatment options, it's important to know how that affects your reproduction. So how does it affect your ovaries in the short term, in the long term, um, in any way possible. So. Once a patient is initially referred from their oncologist to myself or any other fertility specialist, they come into my office and we just have a 30 minute conversation really talking about family planning goals. **Dr. Nirali Jain:** Any kids that they've had in the past either naturally conceived or through um, IVF, and then we talk about where they're at in their relationship. Are they married, are they not? Are they with a partner, [00:04:00] a male partner, a female partner, whatever it might be. It's important to know the social standpoint, um, especially in this sensitive phase of life. **Dr. Nirali Jain:** So patient patients usually spend anywhere from 30 minutes to an hour. Um, just kind of talking through where they're at, how they're feeling, what their ultimate childbearing goals are. And then from there we do an ultrasound and that's when I'm really able to see, you know, the, the reproductive status. **Dr. Nirali Jain:** So what do the ovaries look like? What does the uterus look like? Is there something that I need to be concerned about from a baseline GYN standpoint? Um, and all of those conversations are happening in real time. So. I think one of the things is patients come in and they're like, I'm already so overwhelmed with all this information from my oncologist, and now my fertility specialist is throwing all this information at me. **Dr. Nirali Jain:** Luckily, the way I like to frame it is you come in and you just let go. Like you let us do the work because in the background we're the ones talking to your oncologist. We're the [00:05:00] ones giving that feedback and creating a timeline with your oncologist. Um, and really I think just getting in the door is the hardest part. **Dr. Nirali Jain:** So once patients are here to see us, we go through the whole workup. We do anything that we would do for a normal patient that came in for fertility preservation. And then based off of where they're at in their journey, we talk about what makes sense for them, whether that means freezing embryos, freezing eggs, they're very similar in terms of the, the few weeks leading up to the egg retrievals. **Dr. Nirali Jain:** So I have that whole conversation just at the initial visit. And then from there we talk about the timeline behind the scenes and make sure that it works with their lives before moving forward. **Michelle Oravitz:** So for people listening to this, why, and this might be an obvious question, but to some it might not be,  **Dr. Nirali Jain:** Mm-hmm. **Michelle Oravitz:** why would somebody want to preserve. eggs or sperm. 'cause I've had actually some couples  **Dr. Nirali Jain:** Yep. **Michelle Oravitz:** come to me where the husband preserved the sperm and they had to go through IVF just because he was going [00:06:00] through cancer treatments. So he had to preserve the sperm ahead of time.  **Dr. Nirali Jain:** Mm-hmm. **Michelle Oravitz:** people need to consider doing that before doing cancer treatments?  **Dr. Nirali Jain:** So there are certain cancer treatments that do affect the ovaries and the sperm health, and you know, for men and women, it affects your reproductive organs. In a similar way, um, depending on the type of chemotherapeutic agent, there are some that are more dangerous in terms of, um, being toxic to your ovaries or toxic to your sperm. **Dr. Nirali Jain:** And those are the instances where we are really thinking about what's the long-term impact because there's medications that oncologists do give patients, and our oncologists are amazing, the ones that we work with, Memorial Sloan Kettering from Reproductive Medical Associates through RMA, um, and. **Dr. Nirali Jain:** They're just so good at what they do and are so well-trained, so they know in the back of their mind, is this going to impact your ovaries or your sperm health or not? Um, and I [00:07:00] think that any chemotherapy, you know, your ovaries are these, these small organs that are constantly turning over follicles every month. **Dr. Nirali Jain:** So every month we're losing those eggs, and if they don't become. If an egg isn't ovulated, it doesn't become a baby, it's just gonna die off. So I counsel even patients that don't have cancer, I counsel them on fertility preservation as young as possible. You know, between the ages of 28 and 35, that's like the best time to preserve your fertility. **Dr. Nirali Jain:** So in cancer patients, there's an extra level added to that where even if they are a little bit younger, a little bit older. Your eggs are not gonna be the same quality. There's gonna be higher level of chromosomal errors, more DNA breakage, um, and, and bigger issues that lead to issues with conceiving naturally afterwards. **Dr. Nirali Jain:** So I think that it's important to consider how that chemotherapy is going to affect them or how surgery would affect them if it was, for example, a GYN cancer where [00:08:00] we're removing a whole ovary, you know, what, what do we have to do to preserve your fertility in that case? And those are important conversations to have. **Michelle Oravitz:** Yeah. for sure. I know that a lot of people are also concerned, you know, with going through the IVF process, you're taking in a lot of estrogen, a lot of hormones, and many cancers are actually estrogen sensitive. So I wanted to talk to you about that. 'cause I know that the data shows that it's. It's been fine, which some people might find surprising, but I wanted you to address that and just kind of **Dr. Nirali Jain:** Yeah. **Michelle Oravitz:** from your perspective.  **Dr. Nirali Jain:** That's so interesting that you asked that question because I actually, my whole I I graduated fellowship last year and my entire, like passion project in fellowship was looking at one of the drugs that we use to suppress the estrogen levels specifically in cancer patients. Um, and I had presented this at a few of our reproductive meetings. **Dr. Nirali Jain:** Um, A SRM is one of our annual meetings where all of the reiss get together. A lot of male fertility [00:09:00] specialists come and we kinda just talk about. Specific things and fertility preservation for cancer patients is, has been an ongoing topic of interest for all of us. Um, and it's important to know that there are different medications that we can offer. **Dr. Nirali Jain:** Letrozole is the one that I, um, have a particular love for and I, uh, you know, I use all the time for my patients, um, for different reasons, but it suppresses the exposure that your body has to estrogen. And there's mixed data, um, out there in terms of, you know, does Letrozole suppression actually impact, you know, does it help or. **Dr. Nirali Jain:** Or does it have no impact on your future risk of cancer after treatment? Um, and that honestly is still up for debate. But what we do know is that there's no increased risk of cancer recurrence in patients that have undergone fertility preservation with or without Letrozole. Um, Letrozole is one of those things that we can give, and the way it works is basically. **Dr. Nirali Jain:** It masks that [00:10:00] conversion. It, it doesn't allow for conversion from those androgens in the male hormones over to estrogen. Um, and so your body doesn't really see that estrogen exposure. It stays nice and low throughout your cycle, and it does help with actually ovarian maturation and getting mature eggs harvested and, um, helps a little bit with, with quality too. **Dr. Nirali Jain:** So I think that it's really nice in terms of having that available to us, but know that. It's not, it's not essential that you have it, really, the data showing plus minus. Um, but there are certain things that we can do to protect the ovaries, protect your exposure to estrogen. Um, and so that shouldn't be top of mind of concern when we're going through fertility preservation, even with an estrogen sensitive cancer. **Michelle Oravitz:** Actually, so, uh, on a different topic, kind of going back to that, so Letrozole versus Clomid, I, it's like a, the questions I personally feel just based on what I've heard and like my own research that Letrozole would be kind of like the more. [00:11:00] Um, the, it's, it's a little better, but I know that it really depends on the person as well.  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** they might do better with Clom, but I'd love to hear your perspective and kind of pick your brain on this.  **Dr. Nirali Jain:** totally. You're choosing all the, all the right questions because these are all of my, my specific interests and niches. So  **Michelle Oravitz:** Oh,  **Dr. Nirali Jain:** Letrozole is basically, you know, we use Letrozole and Clomid in. Patients that don't have cancer and patients that come in for an intrauterine insemination, that's kind of the most common scenario where we're thinking about, you know, which medication is better? **Dr. Nirali Jain:** Letrozole or Clomid and Clomid used to be the, the most common medication that we use, we dose patients, you know, have 50 milligrams of Clomid, give them five days of the medication. It's an oral pill. Feels really easy and. The way it works is really, it recruits more than one follicle, so it really helps with the release of, um, more than one follicle growing more than one follicle in the ovary. **Dr. Nirali Jain:** Um, but it has a little bit [00:12:00] higher of a risk of twins because that's exactly what it's good at. Um, Clomid, not so much in the cancer. In the cancer front, it's not really used there because it's considered, from a scientific perspective, it's considered like a selective estrogen receptor modulator. So it doesn't necessarily suppress your estrogen levels in the same way that Letrozole does versus. **Dr. Nirali Jain:** Letrozole is an aromatase inhibitor, so it really blocks the chemical conversion of one drug or one hormone to the other hormone. Um, the reason we love Letrozole so much, and I don't mean to like gush over Letrozole, but um, it's a mono follicular agent, so it works really well at recruiting one follicle  **Michelle Oravitz:** Mm-hmm.  **Dr. Nirali Jain:** you know, every OB-GYN's nightmare in a way is having multiples when you didn't intend on having multiples at all. **Michelle Oravitz:** so  **Dr. Nirali Jain:** Um. **Michelle Oravitz:** were saying that, um, there's more of a chance of twins, it's Clomid, not letrozole.  **Dr. Nirali Jain:** Yes, there's a higher chance with Clomid versus Letrozole. And I mean, don't get me wrong, there's a chance of twins with [00:13:00] any type of assisted reproductive technology. Even when we're doing single embryo transfers, there's a chance that it's gonna split. So, um, the chance is always there just like it is in the natural world. **Dr. Nirali Jain:** But we know for a fact that. CLO is really good at recruiting many follicles. It's good for certain patients that don't respond well to Letrozole. Um, but Letrozole is kind of our, our go-to drug these days just because of all the benefits that we've seen.  **Michelle Oravitz:** Awesome.  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** These are all fun things to ask because I, I love talking to our eis 'cause there's so much information that I'm always  **Dr. Nirali Jain:** totally. **Michelle Oravitz:** learn a lot from my patients in my own research, but it's really cool. Picking your guys' brains. So another question I have, and I have actually talked to Dr. Andrea Elli, he's been on,  **Dr. Nirali Jain:** Mm-hmm. **Michelle Oravitz:** and he does a lot of endometriosis and, and immune related work as well,  **Dr. Nirali Jain:** Yeah. **Michelle Oravitz:** so. I'd love to know just from your perspective. One thing that I do know from, based on what I've heard is that the, [00:14:00] guess like you were just saying, that breast cancer or estrogen sensitive breast cancer doesn't seem to be affected by IVF cycles, however, and endometriosis lesions do get affected.  **Dr. Nirali Jain:** Yeah. **Dr. Nirali Jain:** that's a great question. So, you know, every, there are so many complex G mind diagnoses that the, that our patients come in with. Um, and endometriosis is a big one because there is clear data that endometriosis is linked to infertility. So we think about, you know, when a patient comes in with endometriosis, we really do think about the different treatment options and what are the short-term and long-term impacts of the hormones that we're giving 'em. **Dr. Nirali Jain:** Um, these days, again, kind of going back to Letrozole, we, letrozole is something that I give all of my endometriosis patients because it helps suppress their estrogen because we know.  **Michelle Oravitz:** interesting.  **Dr. Nirali Jain:** is very responsive to estrogen and leads to this dysfunctional regulation of all the endometrial tissue that can really flare in a, [00:15:00] in a cycle, or shortly after a cycle. **Dr. Nirali Jain:** I. So we really, for endometriosis patients, the, the best treatment is being on birth control because we don't see that hormonal fluctuation. The up and down of the estrogen and the progesterone, that's what leads to those flares. Um, so I really, I watch patients closely after their cycles too, because you definitely can have an endometriosis flare and we say the best treatment for endometriosis is pregnancy, right? **Dr. Nirali Jain:** That's when you're suppressed, that's when you're at your lowest. Um, and patients, my endo patients feel so good in pregnancy because they have. Hormones that are nice in that baseline, they're not getting periods of course. Um, and that's truly, truly the best treatment.  **Michelle Oravitz:** That's interesting.  **Dr. Nirali Jain:** But it is important to consider when you're going through infertility treatments. **Dr. Nirali Jain:** How does my endometriosis affect the short and long-term effects of the fertility medications? And really not to, not to say that they're bad in any way. I think a lot of endometriosis patients go through IVF and have success and do really, really well, and that's kind of the push that they need. [00:16:00] Um, but it's important to be mindful of the bigger picture here. **Dr. Nirali Jain:** It's not just, you're not just a number of. A patient with endo coming in, getting the same protocol. It's really individualized to the extent of your lesions, what symptoms you're having, what grade of endometriosis, where your lesions are. So we're the RAs are thinking about everything before we actually start your protocol. **Michelle Oravitz:** It's crazy how in depth it is, and it's, it, there's just so, it's so multifaceted,  **Dr. Nirali Jain:** Yeah,  **Michelle Oravitz:** when it's females  **Dr. Nirali Jain:** totally. **Michelle Oravitz:** are a little, I mean, they can, you know, there, there's definitely a number of things, but it's not as complicated and interconnected  **Dr. Nirali Jain:** Exactly. Exactly. That's so true. **Michelle Oravitz:** And so one question I actually have, this is kind of really off topic, but something that I was curious about. **Michelle Oravitz:** 'cause I heard about a while  **Dr. Nirali Jain:** Yeah. **Michelle Oravitz:** a, a type of cancer treatment that was used. I'm not sure exactly what it was, but for some reason it actually caused follicles to grow, [00:17:00] or to multiply. And they were **Dr. Nirali Jain:** Interesting. **Michelle Oravitz:** this definitely. Puts, um, the whole idea of like a woman being born with all the follicles she'll ever have on its head, I thought that was really Interesting. **Michelle Oravitz:** Now I learned a little bit about it. I don't think it really went further than that,  **Dr. Nirali Jain:** Mm-hmm. **Michelle Oravitz:** one of those things that they're like, Hmm, this is interesting. I don't know, it was kind of a random side effect of this chemo drug. I dunno if it was a chemo drug or a cancer drug.  **Dr. Nirali Jain:** Yeah.  **Michelle Oravitz:** ever heard of that. **Michelle Oravitz:** So I was just **Dr. Nirali Jain:** I haven't, I mean, that's interesting. I feel like I'd have to look into that because that would be definitely a point of interest for a lot of Reis. But it kind of does go back to the point of, you know, women are really born with all the eggs we're ever gonna have. So it's about a million, and then it just goes down from there. **Dr. Nirali Jain:** And the, by the time you start having periods, I like to kind of show my patients a chart, but you have a couple hundred thousand eggs and you ovulate one egg a month. That's, you know. Able to [00:18:00] progress into a fertilized egg and then into a, an embryo into a baby, um, if that's your goal. But otherwise, patients that are having periods and not trying to actually get pregnant, we're losing hundreds of eggs a month. **Dr. Nirali Jain:** So.  **Michelle Oravitz:** Mm.  **Dr. Nirali Jain:** It's important to kind of think about that decline, and it's important to know that that rate can be faster in patients with cancer, patients with low ovarian reserve. And sometimes when you have the two compounded, that's when a fertility specialist is definitely, you know, in the queue to, to have a discussion with you in terms of what that means and how you can reach your family building goals despite being faced with that, with that challenge. **Michelle Oravitz:** Yeah. **Michelle Oravitz:** I mean, 'cause we know oxidative stress is one of the things that can cause, uh,  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** quality eggs, but it's also can cause cancer. **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** um, similar, you know, like things that really deplete the body could definitely impact. Um, and then what are your thoughts? I know I'm asking you all kinds of random questions, **Dr. Nirali Jain:** I love it. **Michelle Oravitz:** are your thoughts about doing low simulation in certain [00:19:00] circumstances versus high stem? **Michelle Oravitz:** Sometimes people don't respond as well to higher stems.  **Dr. Nirali Jain:** Yeah, that's a great point. I think that it kind of all goes back to creating an individualized protocol. If. A patient's going to a practice and basically just getting a protocol saying, this is our standard. We start with our standard of, you know, I, I think about the standard, which is 300 of the FSH or that pen that you dial up, and then 150 units of that powder vial. **Dr. Nirali Jain:** And we have patients mixing powders all the time, and that's kind of our blanket protocol that we give patients. But that's not really what's happening behind the scenes. And if you're given a protocol that's, and being told, you know, this is kind of what we give to everyone, it's probably not the right fit for you. **Michelle Oravitz:** Yeah, I  **Dr. Nirali Jain:** Um, there are certain patients that respond to a much lower dose and do really, really well, and then some patients that need a much higher dose. Um, and I think it's, that's kind of like the fun part of being an REI of being able to individualize the [00:20:00] protocol to the patient. Um, and I know for a fact there are so many, luckily, you know, we have so many leaders in REI that have been. **Dr. Nirali Jain:** Have dedicated their entire careers to researching these different protocols and how they can help different patients. Um, patients with lower a MH, you know, might benefit from a duo stim protocol, for example. That's kind of the first one that comes to mind, but a protocol where we're using those follicles from the second half of a cycle. **Dr. Nirali Jain:** I would've never thought that those were the follicles that  **Michelle Oravitz:** Oh,  **Dr. Nirali Jain:** would be better than the first half of the cycle,  **Michelle Oravitz:** Wait,  **Dr. Nirali Jain:** but, **Michelle Oravitz:** that. Explain that. Um, because I think that that's kind of a unique  **Dr. Nirali Jain:** mm-hmm.  **Michelle Oravitz:** that I haven't heard of.  **Dr. Nirali Jain:** Yeah, so there's this new day. It's still kind of developing, but um, kind of going back to, you know, what's an individualized protocol? Duo STEM is one of the newer protocols that we've started using. I, I've used it once or twice in patients. Um, but it goes back to the research that shows that you might actually have two different periods of time in a menstrual cycle where you could potentially recruit [00:21:00] follicles. **Dr. Nirali Jain:** You could have a follicular phase where there's a certain cohort of follicles recruited, and then you have a follicle that forms creates a corpus glut.  **Michelle Oravitz:** um, protocols  **Dr. Nirali Jain:** Yep. And then you basically go through the follicular protocol and then a few days after a retrieval, instead of waiting for a new follicular cohort or follicular recruitment from the first half of your menstrual cycle, you actually use the luteal phase and you recruit those follicles that would've actually died off or have been prematurely recruited in a prior cycle. **Dr. Nirali Jain:** So **Michelle Oravitz:** that's So  **Dr. Nirali Jain:** yeah, **Michelle Oravitz:** you just do a similar, I guess, um, medicine,  **Dr. Nirali Jain:** go right back into it.  **Michelle Oravitz:** do the same exact thing, but right after ovulation.  **Dr. Nirali Jain:** Yeah.  **Michelle Oravitz:** Fascinating. That's really interesting.  **Dr. Nirali Jain:** Yeah,  **Michelle Oravitz:** has been your experience with that?  **Dr. Nirali Jain:** I think it's, honestly, it's mixed. Um, so far, you know, our data from fertility and sterility and A SRM, it, it shows support for these DUO STEM [00:22:00] protocols, saying that if patients don't have that great quality of eggs or if they have a very low number, maybe they'd benefit from starting the meds earlier and recruiting follicles. **Dr. Nirali Jain:** A little bit earlier. Um, so we've seen positive results so far. A lot of work to be done in terms of really understanding it. Um, and of course, as a new attending, I have a lot more experience to kind of build on. Um, but I, I have seen success from it. **Michelle Oravitz:** That's fascinating. Are there any other new technologies, like new add-ons, um, that you've seen, that you've found to be really cool or interesting?  **Dr. Nirali Jain:** I think the biggest thing, actually, kind of going back to our whole topic for today is fertility preservation cancer patients. One of the biggest things that I've learned recently is that we used to start fertility, um, patients. You know, only in the beginning of the cycle days, two or three is technically like when most. **Dr. Nirali Jain:** Most clinics, um, start patients, but for our cancer patients, sometimes you don't have that time. You don't wanna wait a full month to [00:23:00] restart, um, your, you know, your menstrual cycle and then do the fertility preservation and then delay chemotherapy a full month. So we started doing what we call random starts. **Dr. Nirali Jain:** So you basically start a patient whenever they come in. You know, it could be the day after your consultation, the day of your consultation. I've kind of seen all of the above. Um, and we've seen really good success with random starts, per se. Um, and we've been doing a lot more of that, where it's not as dependent on where you're at in your cycle. **Michelle Oravitz:** Mm-hmm.  **Dr. Nirali Jain:** Um, obviously there's a difference in outcomes. You might not be a great candidate for it, so definitely it's worth talking to your doctor about it. But it kind of gives relief to our cancer patients where if you have a new cancer diagnosis and you're like, oh, I just finished my period, like, I can't even start a cycle until next month. **Dr. Nirali Jain:** That's not always true. Um, so it's always worth it to go into see a fertility specialist and just get, you know, get the data that you need right away, and then you can make a decision later on. **Michelle Oravitz:** For sure. Um, Yeah. **Michelle Oravitz:** and I wanted to kind of cover a lot of different topics 'cause I know that [00:24:00] some people are gonna wanna hear what you have to say that don't necessarily, or, uh, have cancer. But it is important. I, I think that, you know, if you get to thirties and you haven't gotten married or you don't have a partner, I think it's really important to preserve your fertility in general.  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** important thing. And then if you were going through a cancer diagnosis and you decided to preserve your fertility, um, guess more for women because they're eventually going to be thinking about transfers after they go through treatment. So what are some of the things that they would need to consider as far as that goes? **Michelle Oravitz:** Like after the  **Dr. Nirali Jain:** yeah, **Michelle Oravitz:** then they go through the cancer treatments. Um, and then what, how long should they  **Dr. Nirali Jain:** yeah. Like what does it look like? So I've had patients that come back, you know, in my fellowship training I did a, a couple research projects on patients that came back to pursue an embryo transfer, um, after chemotherapy agent. And basically compared them to how they did, um, [00:25:00] compared to patients that didn't have cancer and just froze their embryos or froze their eggs and then came back to pursue a transfer and. **Dr. Nirali Jain:** I think the, the most reassuring thing from the preliminary data that we have is saying that there's no difference in pregnancy rates and no difference in life birth,  **Michelle Oravitz:** Awesome.  **Dr. Nirali Jain:** of whether they had chemotherapy or not. After freezing those eggs and going through fertility preservation.  **Michelle Oravitz:** Amazing.  **Dr. Nirali Jain:** Um, in terms of where your body needs to be, I think the oncologist, we, we wait for their green light. **Dr. Nirali Jain:** We wait for their signal to say, you know, she's safe to carry a pregnancy.  **Michelle Oravitz:** Mm-hmm.  **Dr. Nirali Jain:** And then once we do that, we basically treat you like any other patient. So if you're coming in for a cycle, if you're having periods, then it's reasonable to try a natural cycle protocol, wait for your body to naturally ovulate an egg. **Dr. Nirali Jain:** And instead of obviously hoping that egg will fertilize, we, um, use a corpus luteum. We use the progesterone from the corpus luteum to really support this embryo being implanted into the uterus. Um. Yeah. [00:26:00] And then there's also another side. I mean, some patients don't get their periods back and they always ask like, what if I never get my period back? **Dr. Nirali Jain:** What if I'm just like in menopause because of the chemotherapy agents? And for that, we can start you on a synthetic protocol or basically an estrogen dependent protocol where you take an estrogen pill for a certain number of days. We monitor your lining, then we start progesterone, um, to support your hormones from that perspective instead of relying on your ovaries to release the progesterone that they need, um, and then doing the embryo transfer a few, few days after progesterone starts. **Dr. Nirali Jain:** So there's definitely different protocols depending on where your menstrual health is at after the chemotherapy or after the cancer treatment. Um, but it's important to kind of just know that. That there's options. It doesn't mean that it's the end of the road if you all of a sudden stop getting your period. **Michelle Oravitz:** Yeah, for sure. I mean, 'cause you, technically speaking, you can really control a lot of that. More so for transfers  **Dr. Nirali Jain:** Yep. **Michelle Oravitz:** Retrievals really is kind of like what [00:27:00] eggs you have, what the quality is. But people can be in complete menopause and you guys can still control their cycles for transfer, which is kind of. A huge difference  **Dr. Nirali Jain:** Yeah,  **Michelle Oravitz:** in the  **Dr. Nirali Jain:** exactly. That's exactly right. Yeah. **Michelle Oravitz:** interesting. Any other, um, new, new things that you're, you guys are excited about? I always like to hear about like the new and upcoming things  **Dr. Nirali Jain:** Of course.  **Michelle Oravitz:** actually before, which I thought was fascinating. Yeah.  **Dr. Nirali Jain:** I feel like there's always like updates and, and new data and things like that coming out, but just know, I think it's important for patients to know, like we're constantly, we're, the reason I chose to even pursue this field was because it's new. Right. There's something that we are discovering every day, every year, and that's what makes our, our conferences so important to attend, um, to really just stay up to date. **Dr. Nirali Jain:** Um, but we are, uh, constantly updating our embryology standards, the way we thaw our eggs, and the success rate associated with a thaw and [00:28:00] how we treat our embryos and the media that we use, right? Like, so we're really thinking about the basic science perspective every single day, and that's what makes this field so unique. **Michelle Oravitz:** It is really awesome. And so do you guys specialize specifically on, um. Egg freezing and, and I mean specific fertility preservation in patients that do that have cancer that are going through treatments, do you guys specialize specifically in that? I mean, I know you do range  **Dr. Nirali Jain:** Yeah. Yeah, because it's such a small community, we all have our own niches and we all kind of have our own interests and  **Michelle Oravitz:** Yeah.  **Dr. Nirali Jain:** no like specific training. There are a couple courses that you take that I took in in training as well, just to kind of understand what it sounds like to, I. Council of fertility preservation, patient with and without cancer. **Dr. Nirali Jain:** Um, and then, you know, you kind of just learn by experience and you form a niche for something that you're passionate about. 'cause that's what makes you, you know, really thorough in, in your treatment. [00:29:00] So that's one of my interests. Um, and, but I would say,  **Michelle Oravitz:** training for that. It's just like  **Dr. Nirali Jain:** yeah, **Michelle Oravitz:** just know how to treat that in  **Dr. Nirali Jain:** exactly.  **Michelle Oravitz:** especially if you're interested in doing that.  **Dr. Nirali Jain:** Exactly. That's exactly right. It's kind of, it just comes with the experience comes with your mentors and who you're surrounded by, and everyone kind of helps each other get to that point. But there are several specialists in our practice at RMA that specialize specifically in fertility preservation in cancer patients. **Dr. Nirali Jain:** So we have a close communication with our oncologist and they know who to refer to within the practice because everyone has their own little interests.  **Michelle Oravitz:** Amazing.  **Dr. Nirali Jain:** Yeah. **Michelle Oravitz:** Um, definitely. I, like I said, I really enjoy picking your brain because it's a lot of fun for me. I, I do  **Dr. Nirali Jain:** Totally.  **Michelle Oravitz:** acupuncture, so  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** and I, I think that it's just so crazy that our fields don't work together. I mean, we kind of do, but I think, I just feel like it would be so great  **Dr. Nirali Jain:** exactly.[00:30:00]  **Michelle Oravitz:** the expertise because you guys have immense. Benefits like in, in, uh, technology and incredible innovations and, and then the natural aspect of really understanding the, the body. And I, I just think that it would work so amazing together if it was more of like a thing. 'cause it, I know in China they actually combine the two  **Dr. Nirali Jain:** Yeah.  **Michelle Oravitz:** eastern.  **Dr. Nirali Jain:** Yeah, I mean I think that that's so important and there is data that shows, you know, there's actually a recent study that came out just a few weeks ago on the benefits of acupuncture for fertility patients. And we know that, I mean, I recommend it to all of my patients, specifically the day of the embryo transfer. **Dr. Nirali Jain:** We, luckily, we offer it on site at RMA and we have acupuncturists that come in and, and do a session before and after the embryo transfer, and I think. A lot of that is targeted towards stress relief. But I also think that holistically it's important to feel at your best when we're doing something that's so crucial to your, to your health. **Dr. Nirali Jain:** So to really focus on the diet, focus on stress relief, [00:31:00] focus on meditation, yoga, whatever it takes to get to your best wellbeing when you're going through fertility treatments, um, is so important. So I appreciate  **Michelle Oravitz:** Mm-hmm.  **Dr. Nirali Jain:** like you that really specialize in the other side of. Of this, because I do consider it still part of the holistic medicine that we need to really maximize success for our patients. **Michelle Oravitz:** Awesome. Well,  **Dr. Nirali Jain:** Yeah, **Michelle Oravitz:** Jane, this is such a pleasure Of talking to you. You've given us some, so much great information and we've definitely dived into a, do a topic that I don't typically, I haven't yet spoken about. But, um, that being said, it's such an important topic to talk about. And thank you so much for coming on today. **Michelle Oravitz:** Oh,  **Dr. Nirali Jain:** course. **Michelle Oravitz:** I get off, how can people find you?  **Dr. Nirali Jain:** That's a great question. So I have, um, a social media page. I, it's called Expert nc. So like EGG,  **Michelle Oravitz:** I  **Dr. Nirali Jain:** um, expert nc. Try, tried to make it a little bit humorous. Um, but I'm all over social [00:32:00] media and would love to hear from anyone that is listening. I, you know, every, every day I get different, um, dms and I'm happy to respond. **Dr. Nirali Jain:** I love hearing about everyone else's. Stories and things like that. Um, so that is kind of my main, main social media platform. Um, and then through like RMA and Reproductive Medical Associates, we also have a YouTube channel. We have an Instagram page, um, of our office available, um, as well that is public. **Dr. Nirali Jain:** So you can find us pretty easily if you just kind of hit Google. But um, yeah, I'm kind of developing my social media platform as the expert and I hope it grows.  **Michelle Oravitz:** Love it. Great.  **Dr. Nirali Jain:** Yeah.  **Michelle Oravitz:** was such a pleasure talking to you. Thank you. so much **Dr. Nirali Jain:** Thank you. **Michelle Oravitz:** today.  **Dr. Nirali Jain:** Of course. Thank you so much for having me.  [00:33:00]   

Ras de tierra: Doctora Ana Laura Magaloni, abogada de Nuestro Futuro AC

What makes a residence hall more than just a place to sleep? In this episode, we explore how residence halls can become powerful hubs for belonging, connection, and student growth. Our guest, Dr. Amy Lorenz, shares insights on designing inclusive residential communities, the vital role of RAs and other student leaders, and the intentional programs that help students feel seen, supported, and engaged from day one. Dr. Lorenz serves as the Director of Residence Life at the University of North Florida. Amy's research focuses on student, faculty, and staff experiences in living-learning communities. Amy's professional interests are in student learning and development, peer mentoring, and co-curricular learning experiences.  Additional Resources CITI Program's Higher Education Solution: https://about.citiprogram.org/solutions/higher-education/  

This week hosts Tiffany Cross, Angela Rye, and Andrew Gillum speak with the Mayor of Newark, Ras Baraka. The Mayor made headlines last Friday after he was arrested by ICE while protesting a new ICE detention facility in his home city. Mayor Baraka’s arrest comes in the context of Trump’s sprawling campaign of retribution against his “political enemies.” From law firms, to judges, to universities and elected officials–Trump is weaponizing the federal government against anyone he perceives to have wronged him. The legal attacks are often effective even if his administration doesn’t win the case… Today our hosts discuss government retaliation. The chilling effect of these attacks could have long term impacts on free speech, the application of justice, and our ability to govern. Mayor of Newark, New Jersey, Ras J. Baraka is a Newark native, poet, and educator. Under his leadership, Newark achieved a 60-year low in crime, replaced 23,000 lead service lines, and reduced homelessness by 57%. A member of Alpha Phi Alpha, Ras is a lifelong advocate for equity and opportunity. He’s now running a campaign for Governor of New Jersey. If you’d like to submit a question, check out our tutorial video: http://www.instagram.com/reel/C5j_oBXLIg0/ and send to @nativelandpod. We are 537 days away from the midterm elections. Welcome home y’all! —--------- We want to hear from you! Send us a video @nativelandpod and we may feature you on the podcast. Instagram X/Twitter Facebook NativeLandPod.com Watch full episodes of Native Land Pod here on YouTube. Native Land Pod is brought to you by Reasoned Choice Media. Thank you to the Native Land Pod team: Angela Rye as host, executive producer and cofounder of Reasoned Choice Media; Tiffany Cross as host and producer, Andrew Gillum as host and producer, and Lauren Hansen as executive producer; Loren Mychael is our research producer, and Nikolas Harter is our editor and producer. Special thanks to Chris Morrow and Lenard McKelvey, co-founders of Reasoned Choice Media. Theme music created by Daniel Laurent.See omnystudio.com/listener for privacy information.

Manifestation requires more than just wishful thinking—it demands a scientific approach that aligns our beliefs, attention, and actions with specific outcomes. We explore the neuroscience behind manifestation and provide a practical five-step protocol to make it work in your life.• Manifestation is the process of aligning beliefs, attention, and actions with specific outcomes• The reticular activating system (RAS) filters information based on what we're focused on• Neuroplasticity allows our thoughts and intentions to physically reshape our brain's structure• Mirror neurons and embodiment help normalize our desired version of ourselves• Energetic congruence ensures our emotions align with our desired outcomes• Clarify your outcome by writing it down specifically as if it's already happening• Spend two minutes daily visualizing your goal and anchoring it with a physical cue• Journal as the version of you who has already achieved your goal• Take daily micro-actions that align with your desired outcome• Regulate your nervous system to feel safe receiving what you want• Manifestation combines intention, aligned action, and nervous system safetyWant more tips and strategies for creating your best life? Visit www.jenncody.com and sign up for the free Weekly Balance newsletter.Thanks for listening! Connect With Me:

Kain Medrano was selected by the #commanders with the 205th pick of the 2025 #NFL draft. Medrano has some very intriguing #RAS scores and his story is that of an easy to root for athlete. Medrano has some interesting player comparsions as well. Tune in to this detailed breakdown of Kain Medrano of your Washington Commanders.

In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.

11:16 - Guest: Kent Lee Platte, creator of the groundbreaking Relative Athletic Score (RAS) metric for NFL Draft prospects, on the Commanders for each of their two NFL Drafts with Adam Peters as general manager being No. 1 in the NFL in average RAS for players taken in the draft, whether prioritizing players who test very well athletically is a wise NFL Draft strategy, why offensive tackle Josh Conerly Jr. most stands out regarding players selected by the Commanders in the 2025 NFL Draft in terms of RAS, perspective on receiver Jaylin Lane and running back Jacory Croskey-Merritt in terms of RAS, when an NFL player's athletic prime truly is and much more 32:45 - Capitals: preview of the Caps' best-of-seven series against the Carolina Hurricanes in the second round of the Stanley Cup Playoffs 44:40 - Nationals: discussion of the Nats winning two out of three games at the Cincinnati Reds 56:40 - Orioles: breakdown of the O's losing two out of three games against the Kansas City Royals Download the PrizePicks app and use the promo code "Galdi" for $50 instantly after you play your first $5 lineup The Nace Law Group, Accident & Injury Lawyers - 202-902-7611 and make sure that you mention that Al Galdi sent you Call Nova Fireplace And Stove at 571-513-3803, mention that Al Galdi sent you and receive $50 off any fireplace service before Sept. 1, 2025 - this includes cleaning, safety inspection, tune-up and diagnostic work For advertising inquiries, email Sales@BlueWirePods.com Please note that time stamps may be slightly off depending on rotating national ads 

Episode 694 - Are your emotions keeping you stuck in the same patterns? Fear, doubt, and anxiety are not just feelings—they shape your brain, nervous system, and reality. In this podcast, I'll break down how survival emotions hijack your mind, how brain wave states impact manifestation, and how you can regulate your nervous system to rewire your subconscious. Plus, I'll explain how the Reticular Activating System (RAS) controls what you notice in life—and how to use it to attract what you truly want.

With the NFL Draft just around the corner, Ryan Schlipp dives deep into Brian Gutekunst's recent press conference and the chaos of fan speculation. Ryan breaks down the ongoing debate over traits vs. production, the misconceptions around the Packers' use of RAS, and the wild draft rumors swirling around Will Johnson and Jaire Alexander. From projecting college talent to handling trade-up scenarios, this episode is a full pre-draft masterclass on how the Packers build their board. Plus, thoughts on Quay Walker, Devonte Wyatt, and the mystery of Tetero McMillan. To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast

On today's show, Ross Uglem is joined by RAS creator Kent Lee Platte to explain the RAS tool and how it's best utilized. Don't miss it!Packers Draft Guide: https://draftguide.gumroad.com/l/greenbay25/dailyHomage: http://homage.sjv.io/Packers

With the NFL Draft just around the corner, Ryan Schlipp dives deep into Brian Gutekunst's recent press conference and the chaos of fan speculation. Ryan breaks down the ongoing debate over traits vs. production, the misconceptions around the Packers' use of RAS, and the wild draft rumors swirling around Will Johnson and Jaire Alexander. From projecting college talent to handling trade-up scenarios, this episode is a full pre-draft masterclass on how the Packers build their board. Plus, thoughts on Quay Walker, Devonte Wyatt, and the mystery of Tetero McMillan. To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast

Download the FREE Hunger Study Guide now at: